AstraZeneca AZN
AstraZeneca is a global pharmaceutical company that develops, manufactures, and commercializes prescription medicines in therapeutic areas such as oncology, cardiovascular, renal and metabolic diseases, and respiratory and immunology. AstraZeneca shows solid financial health (ND/EBITDA 1.38) and a robust competitive moat (ROE 21.96%, gross margin 81.69%), but its earnings growth is modest (2.50%) and cash conversion is weak (24.65%), which weighs on its valuation and overall appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
AstraZeneca is a global pharmaceutical company that develops, manufactures, and commercializes prescription medicines in therapeutic areas such as oncology, cardiovascular, renal and metabolic diseases, and respiratory and immunology. AstraZeneca shows solid financial health (ND/EBITDA 1.38) and a robust competitive moat (ROE 21.96%, gross margin 81.69%), but its earnings growth is modest (2.50%) and cash conversion is weak (24.65%), which weighs on its valuation and overall appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.6 |
| Quality / Moat | 7.0 |
| Valuation | 5.3 |
| Growth | 5.4 |
| Dividend | 6.7 |
| Momentum | 4.5 |
| Risk & Context | 9.1 |
OVERALL SCORE: 6.5/10
Context and risks
Moderate regulatory risk in the UK and drug pricing pressure in key markets. The macro context of rates and energy does not materially affect a pharmaceutical company with this profile.
News considered in the analysis
- AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market? — La pregunta sobre la capacidad de la medicina de precisión para compensar un mercado de cáncer de mama más reducido sugiere presión competitiva en una de sus áreas clave, aunque es una especulación de análisis.
- 3 British AI Stocks With Revenue Up To £61 Billion — Listículo genérico que menciona a AstraZeneca entre otras empresas británicas; sin información nueva sobre la compañía.
- Sector Update: Healthcare Stocks Higher Late Afternoon — Ruido de mercado sectorial sin información específica sobre AstraZeneca.
- Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading — Ruido de mercado sectorial sin información específica sobre AstraZeneca.
- Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent — Noticia sobre un competidor (Sanofi) que no menciona a AstraZeneca; sin impacto directo.
Verdict: Hold; business quality is high, but growth and cash generation do not justify an aggressive position at current levels.
Main risk: Weak cash conversion (24.65%) and increasing competition in oncology, especially in breast cancer, could limit AstraZeneca's ability to sustain growth and shareholder returns.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →